Isis Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

Ionis Pharmaceuticals, Inc.

Charles John Guinosso

Phillip Dan Cook

Muthiah Manoharan

Andrew Mamoru Kawasaki

Thomas W Bruice

Richard Holmes Griffey

David J Ecker

Thazha P Prakash

Balkrishen Bhat

David Brian Olsen

Malcolm Maccoss

Pei-Pei Kung

Daniel Peter McGee

Philip D Cook

Allister S Fraser

Daniel Peter Claude McGee

Haoyun An

Oscar L Acevedo

Kandasamy Ramasamy

Neelima Bhat

Lawrence C Kuo

Steven S Carroll

Robert L Lafemina

Marija Prhavc

Anne B Eldrup

Amy L Himmelberger

Compounds are provided containing purine nucleotides that bear moieties X at the 2' position thereof wherein X is R&#x2014;(R); Ris C-Calkyl, C-Calkenyl or C-Calkynyl; Ris halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides; and n is an integer from 0 to about 6. Such compounds are useful for modulating the synthesis of proteins.

Oligonucleotides containing 2'-O-modified purines

Nucleosides and oligonucleosides functionalized to include alkylamino functionality, and derivatives thereof. In certain embodiments, the compounds of the invention further include steroids, reporter molecules, reporter enzymes, lipophilic molecules, peptides or proteins attached to the nucleosides through the alkylamino group.

Amine-derivatized nucleosides and oligonucleosides

Nucleotides and oligonucleosides functionalized to include alkylamino functionality, and derivatives thereof. In certain embodiments, the compounds of the invention further include steroids, reporter molecules, reporter enzymes, lipophilic molecules, peptides or proteins attached to the nucleotides through the alkylamino group.

Nucleosides and oligonucleosides functionalized to include alkylamino functionality, and derivatives thereof. In certain embodiments, the compounds of the invention further include steriods, reporter molecules, reporter enzymes, lipophilic molecules, peptides or proteins attached to the nucleosided through the alkylamino group.

Modified oligonucleotides containing at least one 2&prime;,5&prime;-internucleotide linkage are provided. The oligonucleotides of the invention may also bear additional substituents at the 2&prime;- and 3&prime;-positions.

Modified oligonucleotides

Compositions and methods for modulating the activity of RNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. The reactive portions preferably comprise one or two imidazole functionalities conjugated to the targeting oligonucleotide via linkers with or without intervening intercalating moieties. Therapeutics, diagnostics and research methods also are disclosed, as are synthetic nucleosides and nucleoside fragments that can be elaborated into oligonucleotides.

Compositions and methods for modulating RNA

Compositions and methods for modulating the activity of RNA are disclosed, In accordance with preferred embodiments, antisense compositions are prepared targeting reactive portions. The reactive portions preferably comprise one or two imidazole functionalities conjugated to the targeting oligonucleotide via linkers with or without intervening intercalating moieties. Therapeutics, diagnostics and research methods also are disclosed, as are synthetic nucleosides and nucleoside fragments that can be elaborated into oligonucleotides.

Compositions and methods for modulating the activity of RNA and DNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. Reactive portions which act, alternatively, through phosphorodiester bond cleavage, through backbone sugar bond cleavage or through base modification are preferrably employed. Groups which improve the pharmacodynamic and pharmacokinetic properties of the oligonucleotides are also useful in accordance with certain embodiments of this invention. Delivery of the reactive or non-reactive functionalities into the minor groove formed by the hybridization of the composition with the target RNA is also preferrably accomplished. Therapeutics, diagnostics and research methods and also disclosed. Synthetic nucleosides and nucleoside fragments are also provided useful for elaboration of oligonucleotides and oligonucleotide analogs for such purposes.

Compound for detecting and modulating RNA activity and gene expression

Processes for preparing 2&prime;-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3&prime;-O-phosphoramidites include the steps of alkylating nucleoside precursors, adding suitable blocking groups and phosphitylating. For the guanosine 2&prime;-O-alkylated 3&prime;-O-phosphoramidites, alkylation is effected on 2,6-diamino-9-(&bgr;-D-ribofuranosyl) purine followed by deamination. For uridine 2&prime;-O-alkylated 3&prime;-O-phosphoramidites, alkylation is effect on a dialkyl stannylene derivative of uridine. For cytidine 2&prime;-O-alkylated 3&prime;-O-phosphoramidites, alkylation is effected directly on cytidine. Alkylation is effected directly upon 2,6-diaminopurine.

Process for the preparation of 2&prime;-O-alkyl-guanosine, cytidine, and uridine phosphoramidites

Novel macrocyclic compounds are constructed to include a ring or ring system having two bridgehead atoms with a bridge extending between the bridgehead atoms. Located in at least the bridge are two or more nitrogenous moieties that are derivatized with chemical functional groups. The ring or ring systems can include further nitrogenous moieties, either as ring atoms or on pendant groups attached to the ring. These can also be derivatized with chemical functional groups. The totality of the chemical functional groups imparts certain conformational and other properties to the compounds. In accordance with certain embodiments of the invention, libraries of such compounds are prepared utilizing permutations and combinations of the chemical functional groups and the nitrogenous moieties to build complexity into the library.

Macrocyclic compounds having nitrogen-containing linkages

Provided are compounds of formula (I) ##STR1## wherein X, Y and Z are independently CH or N; n is 0 or 1; R.sub.1 is selected from OH, alkoxy, aryloxy, aralkyloxy and guanidinyl; R.sub.2 and R.sub.3 are independently selected from H, halogen, amino, hydroxyl, nitro, cyano and carboxyl; R.sub.4 is H, alkyl or acyl; R.sub.5 is selected from H, hydroxyl, halogen, nitro, alkyl, alkoxy, amino, cyclic amino, alkylamino, arylamino and aralkylamino wherein the alkyl, aryl and cyclic moieties are optionally substituted; R.sub.6 and R.sub.7 are independently selected from H, alkyl, alkoxy, halogen and amino; and R.sub.8 and R.sub.9 are independently selected from H, C.sub.1-4 alkyl, alkoxy, acyl, acyloxy, alkoxycarbonyl, hydroxyl, halogen, amino and carboxyl. The compounds have therapeutic or prophylactic use for treating bacterial infection in mammals.

Antibacterial quinazoline compounds

Processes for preparing 2'-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3'-O-phosphoramidites include the steps of alkylating nucleoside precursors, adding suitable blocking groups and phosphitylating. For the guanosine 2'-O-alkylated 3'-O-phosphoramidites, alkylation is effected on 2,6-diamino-9-(.beta.-D-ribofuranosyl)purine followed by deamination. For uridine 2'-O-alkylated 3'-O-phosphoramidites, alkylation is effect on a dialkyl stannylene derivative of uridine. For cytidine 2'-O-alkylated 3'-O-phosphoramidites, alkylation is effected directly on cytidine. Alkylation is effected directly upon 2,6-diaminopurine.

Growing community of inventors

Vista, CA, United States of America

Charles John Guinosso